CPIX
Income statement / Annual
Last year (2023), Cumberland Pharmaceuticals Inc.'s total revenue was $39.55 M,
a decrease of 5.85% from the previous year.
In 2023, Cumberland Pharmaceuticals Inc.'s net income was -$6.28 M.
See Cumberland Pharmaceuticals Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$39.55 M
|
$42.01 M
|
$35.99 M
|
$37.44 M
|
$34.39 M
|
$40.74 M
|
$41.15 M
|
$33.03 M
|
$33.52 M
|
$36.90 M
|
| Cost of Revenue |
$6.07 M |
$9.12 M |
$8.81 M |
$8.65 M |
$7.42 M |
$7.38 M |
$7.37 M |
$5.96 M |
$4.97 M |
$5.05 M |
| Gross Profit |
$33.49 M |
$32.89 M |
$27.17 M |
$28.79 M |
$26.97 M |
$33.36 M |
$33.78 M |
$27.07 M |
$28.55 M |
$31.85 M |
| Gross Profit Ratio |
0.85 |
0.78 |
0.76 |
0.77 |
0.78 |
0.82 |
0.82 |
0.82 |
0.85 |
0.86 |
| Research and Development
Expenses |
$5.83 M
|
$6.69 M
|
$5.68 M
|
$5.77 M
|
$6.87 M
|
$7.32 M
|
$3.90 M
|
$3.19 M
|
$3.85 M
|
$3.39 M
|
| General & Administrative
Expenses |
$10.65 M
|
$10.18 M
|
$9.78 M
|
$10.20 M
|
$9.97 M
|
$10.41 M
|
$10.03 M
|
$8.56 M
|
$7.61 M
|
$8.40 M
|
| Selling & Marketing
Expenses |
$18.45 M
|
$16.66 M
|
$15.02 M
|
$14.77 M
|
$15.28 M
|
$20.26 M
|
$21.49 M
|
$14.55 M
|
$13.99 M
|
$14.90 M
|
| Selling, General &
Administrative Expenses |
$29.10 M
|
$26.84 M
|
$24.80 M
|
$24.96 M
|
$25.25 M
|
$30.66 M
|
$31.52 M
|
$23.12 M
|
$21.60 M
|
$23.30 M
|
| Other Expenses |
$8.10 M |
$5.07 M |
$4.37 M |
$4.43 M |
$4.13 M |
$2.77 M |
$2.44 M |
$2.19 M |
$1.99 M |
$1.60 M |
| Operating Expenses |
$43.04 M |
$38.60 M |
$34.85 M |
$35.17 M |
$36.26 M |
$40.75 M |
$37.86 M |
$28.50 M |
$27.44 M |
$28.29 M |
| Cost And Expenses |
$49.11 M |
$47.72 M |
$43.66 M |
$43.82 M |
$43.68 M |
$48.13 M |
$45.23 M |
$34.46 M |
$32.41 M |
$33.34 M |
| Interest Income |
$286,854.00 |
$98,405.00 |
$26,081.00 |
$75,345.00 |
$243,364.00 |
$564,484.00 |
$299,326.00 |
$204,661.00 |
$209,183.00 |
$251,447.00 |
| Interest Expense |
$667,861.00 |
$585,995.00 |
$98,031.00 |
$263,627.00 |
$246,186.00 |
$195,848.00 |
$92,904.00 |
$106,392.00 |
$73,856.00 |
$67,074.00 |
| Depreciation &
Amortization |
$5.77 M
|
$5.33 M
|
$4.61 M
|
$4.75 M
|
$4.40 M
|
$2.98 M
|
$2.65 M
|
$2.40 M
|
$2.25 M
|
$1.99 M
|
| EBITDA |
-$710,850.00
|
$332,919.00
|
-$857,833.00
|
-$1.56 M
|
-$4.64 M
|
-$8.19 M
|
-$1.13 M
|
$1.17 M
|
$3.57 M
|
$5.73 M
|
| EBITDA Ratio |
-0.02 |
-0.01 |
-0.02 |
-0.04 |
-0.13 |
-0.09 |
-0.03 |
0.04 |
0.11 |
0.16 |
| Operating Income Ratio
|
-0.16
|
-0.14
|
-0.21
|
-0.17
|
-0.27
|
-0.18
|
-0.1
|
-0.04
|
-0.03
|
0.1
|
| Total Other
Income/Expenses Net |
-$74,178.00
|
$123,740.00
|
$2.12 M
|
-$188,282.00
|
-$2,822.00
|
$368,636.00
|
$206,422.00
|
$98,269.00
|
$135,327.00
|
$184,373.00
|
| Income Before Tax |
-$6.28 M |
-$5.58 M |
-$5.56 M |
-$6.57 M |
-$9.29 M |
-$7.02 M |
-$3.87 M |
-$1.33 M |
$1.25 M |
$3.74 M |
| Income Before Tax Ratio
|
-0.16
|
-0.13
|
-0.15
|
-0.18
|
-0.27
|
-0.17
|
-0.09
|
-0.04
|
0.04
|
0.1
|
| Income Tax Expense |
$45,769.00 |
$68,850.00 |
$34,891.00 |
$55,902.00 |
-$79,316.00 |
$16,636.00 |
$4.17 M |
-$330,924.00 |
$575,829.00 |
$1.38 M |
| Net Income |
-$6.28 M |
-$5.65 M |
-$5.60 M |
-$6.63 M |
-$9.21 M |
-$6.96 M |
-$7.98 M |
-$944,683.00 |
$731,351.00 |
$2.42 M |
| Net Income Ratio |
-0.16 |
-0.13 |
-0.16 |
-0.18 |
-0.27 |
-0.17 |
-0.19 |
-0.03 |
0.02 |
0.07 |
| EPS |
-0.44 |
-0.39 |
-0.38 |
-0.44 |
-0.6 |
-0.45 |
-0.5 |
-0.06 |
0.04 |
0.14 |
| EPS Diluted |
-0.44 |
-0.39 |
-0.38 |
-0.44 |
-0.6 |
-0.45 |
-0.5 |
-0.0582 |
0.04 |
0.14 |
| Weighted Average Shares
Out |
$14.30 M
|
$14.56 M
|
$14.90 M
|
$15.16 M
|
$15.40 M
|
$15.57 M
|
$15.91 M
|
$15.74 M
|
$16.72 M
|
$17.62 M
|
| Weighted Average Shares
Out Diluted |
$14.30 M
|
$14.56 M
|
$14.90 M
|
$15.16 M
|
$15.40 M
|
$15.61 M
|
$15.91 M
|
$16.24 M
|
$17.09 M
|
$17.90 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
